Jeffrey C Goh
Overview
Explore the profile of Jeffrey C Goh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
2870
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emmett L, Subramaniam S, Crumbaker M, Joshua A, Sandhu S, Nguyen A, et al.
Lancet Oncol
. 2025 Feb;
26(3):291-299.
PMID: 39956124
Background: Interim analysis of the ENZA-p trial showed improved prostate-specific antigen (PSA) progression-free survival with the addition of lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 to enzalutamide as first-line treatment of metastatic...
2.
Azad A, Gurney H, Campbell A, Goh J, Rathi V
Asia Pac J Clin Oncol
. 2025 Jan;
PMID: 39825869
Some patients with metastatic castration-resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1 and BRCA2. Tumors with BRCA mutations exhibit sensitivity to...
3.
Oaknin A, Monk B, de Melo A, Kim H, Kim Y, Lisyanskaya A, et al.
Eur J Cancer
. 2025 Jan;
216:115146.
PMID: 39798514
Aim: Cemiplimab has demonstrated significantly longer survival than physician's choice of chemotherapy in patients with recurrent cervical cancer after first-line platinum-containing chemotherapy. We report the final survival analysis from the...
4.
Motzer R, Bex A, Russo P, Tomita Y, Cutuli H, Rojas C, et al.
J Clin Oncol
. 2024 Sep;
43(2):189-200.
PMID: 39303200
Purpose: CheckMate 914 is a two-part, randomized phase III trial evaluating adjuvant nivolumab plus ipilimumab (part A) or adjuvant nivolumab monotherapy (part B) versus placebo in mutually exclusive populations of...
5.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua A, Weickhardt A, et al.
Lancet Oncol
. 2024 Apr;
25(5):563-571.
PMID: 38621400
Background: Enzalutamide and lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data...
6.
Grunwald V, Powles T, Eto M, Kopyltsov E, Rha S, Porta C, et al.
Front Oncol
. 2024 Mar;
13:1343027.
PMID: 38495081
[This corrects the article DOI: 10.3389/fonc.2023.1223282.].
7.
Motzer R, Porta C, Eto M, Powles T, Grunwald V, Hutson T, et al.
J Clin Oncol
. 2024 Jan;
42(11):1222-1228.
PMID: 38227898
JCO We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up...
8.
Tariq A, Pearce A, Rhee H, Kyle S, Raveenthiran S, Pelecanos A, et al.
Eur Urol Focus
. 2024 Jan;
10(5):770-778.
PMID: 38195354
Background: Accurate primary staging of renal cancer with conventional imaging is challenging. Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) may serve to improve the accuracy of renal cancer...
9.
Hofman M, Emmett L, Sandhu S, Iravani A, Buteau J, Joshua A, et al.
Lancet Oncol
. 2023 Dec;
25(1):99-107.
PMID: 38043558
Background: The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer progressing after docetaxel. In this Article, we report the...
10.
Conduit C, Davis I, Goh J, Kichenadasse G, Gurney H, Harris C, et al.
BJU Int
. 2023 Nov;
133 Suppl 3:57-67.
PMID: 37986556
Objective: To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non-clear-cell renal cell carcinoma (nccRCC). Materials And Methods: UNISoN...